3,5-二氟苄氯 | 220141-71-9

• 物质功能分类: 化学试剂 - 有机试剂 - 芳烃
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3,5-二氟苄氯
• 中文别名: 3,5-二氟苄基氯；3,5-二氟氯苄
• 英文名称: 3,5-difluorobenzyl chloride
• 英文别名: 1-(chloromethyl)-3,5-difluorobenzene
• CAS: 220141-71-9
• 化学式: C₇H₅ClF₂
• mdl: MFCD01090990
• 分子量: 162.567
• InChiKey: VNGSMSFVLAAOGK-UHFFFAOYSA-N

物化性质

• 沸点：
  82°C 22mm
• 密度：
  1.294±0.06 g/cm3(Predicted)
• 闪点：
  82°C/22mm
• 稳定性/保质期：

  避免与氧化物、水分和碱接触。

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  8
• 危险品标志：
  C
• 安全说明：
  S26,S36/37/39,S45
• 危险类别码：
  R34
• 危险品运输编号：
  3265
• 海关编码：
  2903999090
• 包装等级：
  II
• 危险类别：
  8
• 危险性防范说明：
  P260,P303+P361+P353,P305+P351+P338,P301+P330+P331,P405,P501
• 危险性描述：
  H314
• 储存条件：
  保存方法：密闭、阴凉、通风干燥处

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3,5-Difluorobenzyl chloride
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H314: Causes severe skin burns and eye damage
H318: Causes serious eye damage
P260: Do not breathe dust/fume/gas/mist/vapours/spray
P303+P361+P353: IF ON SKIN (or hair): Remove/Take off immediately all contaminated clothing. Rinse skin with
water/shower
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P301+P330+P331: IF SWALLOWED: Rinse mouth. Do NOT induce vomiting
P405: Store locked up

---

Section 3. Composition/information on ingredients.
Ingredient name: 3,5-Difluorobenzyl chloride
CAS number: 220141-71-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H5ClF2
Molecular weight: 162.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
UN Number: UN3265 Class: 8 Packing group: II
Proper shipping name: CORROSIVE LIQUID, ACIDIC, ORGANIC, N.O.S. (3,5-Difluorobenzyl chloride)

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3,5-二氟苄氯 在 caesium carbonate 、 [双(三氟乙酰氧基)碘]苯 、 potassium iodide 作用下， 以 水 、 乙腈 为溶剂， 反应 5.0h， 生成 1-[(3,5-二氟苯基)甲基]哌啶-4-胺
  参考文献：
  名称：

  THE DESIGN AND SYNTHESIS OF PURINE INHIBITORS OF CDK2. III

  摘要：

  Cyclin-dependent kinases (CDKs) belong to a class of enzymes that control the ability of a cell to enter into and proceed through the cell division cycle. Using purine as a scaffold, we have synthesized a number of nanomolar inhibitors of CDK-2/cyclin E. In this report, the synthesis of a series of piperidine-substituted purine analogs will be presented, as well as some of their in vitro and in vivo biological effects.

  DOI：

  10.1081/ncn-100002493

文献信息

• Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists
  申请人：Bissantz Caterina

  公开号：US20070027173A1

  公开（公告）日：2007-02-01

  The invention relates to indol-3-yl-carbonyl-spiro-piperidine derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the spiro-piperidine head group A and the residues R 1 , R 2 and R 3 are as defined herein. The invention further relates to pharmaceutical compositions containing such compounds, methods for preparing the compounds and pharmaceutical compositions, and their use in the treatment of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxious and depressive disorders.

  本发明涉及作为V1a受体拮抗剂的吲哚-3-基-甲酰基-螺环-哌啶衍生物，其由公式I表示：其中，螺环-哌啶头基A以及残基R1、R2和R3如本文所述定义。本发明进一步涉及含有此类化合物的药物组合物，制备化合物和药物组合物的方法，以及它们在治疗痛经、高血压、慢性心力衰竭、血管升压素不适当分泌、肝硬化、肾病综合征、强迫症、焦虑和抑郁障碍中的用途。
• Indol-3-y-carbonyl-piperidin and piperazin-derivatives
  申请人：Bissantz Caterina

  公开号：US20070027163A1

  公开（公告）日：2007-02-01

  The present invention relates to indol-3-yl-carbonyl-piperidin and piperazin derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the residues R 1 to R 3 are as defined herein. The invention also relates to pharmaceutical compositions containing such compounds, and methods for preparation of the compounds and compositions. The invention further relates to methods for treating dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety and depressive disorders.

  本发明涉及作为V1a受体拮抗剂的吲哒-3-基甲酰哌啶和哌嗪衍生物，其由以下式I表示：其中残基R1至R3如本文所定义。该发明还涉及含有这种化合物的药物组合物，以及制备这些化合物和组合物的方法。该发明还涉及治疗痛经、高血压、慢性心力衰竭、抗利尿素过度分泌、肝硬化、肾病综合征、强迫症、焦虑和抑郁症的方法。
• [EN] SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS<br/>[FR] PYRAZOLO-PYRIDINES HÉTÉROAROMATIQUES SUBSTITUÉES ET LEUR UTILISATION EN TANT QUE MODULATEURS DU RÉCEPTEUR GLUN2B
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2020249785A1

  公开（公告）日：2020-12-17

  Substituted Pyrazolo-pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.

  替代性吡唑并吡啶作为GluN2B受体配体。此类化合物可用于GluN2B受体调节，以及用于治疗由GluN2B受体活性介导的疾病状态、紊乱和条件的药物组合物和方法。
• [EN] METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION<br/>[FR] PROCÉDÉS ET INTERMÉDIAIRES POUR PRÉPARER UN COMPOSÉ THÉRAPEUTIQUE UTILE DANS LE TRAITEMENT D'UNE INFECTION VIRALE PAR RETROVIRIDAE
  申请人：GILEAD SCIENCES INC

  公开号：WO2019161280A1

  公开（公告）日：2019-08-22

  The present disclosure relates to methods and intermediates useful for preparing a compound of formula (I): (I) or a co-crystal, solvate, salt or combination thereof.

  本公开涉及用于制备化合物(I)的方法和中间体，该化合物的结构如下：(I)，或其共晶体、溶剂合物、盐或其组合物。
• A Novel Series of [1,2,4]Triazolo[4,3-a]Pyridine Sulfonamides as Potential Antimalarial Agents: In Silico Studies, Synthesis and In Vitro Evaluation
  作者：Veronika R. Karpina、Svitlana S. Kovalenko、Sergiy M. Kovalenko、Oleksandr G. Drushlyak、Natalya D. Bunyatyan、Victoriya A. Georgiyants、Vladimir V. Ivanov、Thierry Langer、Louis Maes

  DOI：10.3390/molecules25194485

  日期：——

  new and potent antimalarial drugs, we designed the virtual library with three points of randomization of novel [1,2,4]triazolo[4,3-a]pyridines bearing a sulfonamide fragment. The library of 1561 compounds has been investigated by both virtual screening and molecular docking methods using falcipain-2 as a target enzyme. 25 chosen hits were synthesized and evaluated for their antimalarial activity in vitro

  为了开发新的和有效的抗疟疾药物，我们设计了虚拟库，其中包含带有磺胺片段的新型 [1,2,4] 三唑并 [4,3-a] 吡啶的三个随机点。使用 falcipain-2 作为目标酶，通过虚拟筛选和分子对接方法对 1561 种化合物的库进行了研究。合成了 25 个选定的命中并评估了它们在体外针对恶性疟原虫的抗疟活性。3-乙基-N-(3-氟苄基)-N-(4-甲氧基苯基)-[1,2,4]三唑并[4,3-a]吡啶-6-磺酰胺和2-(3-氯苄基)-8 -(piperidin-1-ylsulfonyl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one 显示出良好的体外抗疟活性，抑制浓度 IC50 分别为 2.24 和 4.98 μM。